Skip to main content
Journal cover image

Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study.

Publication ,  Journal Article
Akerblom, A; Wallentin, L; Siegbahn, A; Becker, RC; Budaj, A; Horrow, J; Husted, S; Katus, H; Claeys, MJ; Storey, RF; Asenblad, N; James, SK
Published in: Am Heart J
November 2012

BACKGROUND: To investigate if ticagrelor treatment and other clinical characteristics were associated with increased cystatin C concentrations and if a deterioration in estimated renal function was associated with worse outcome in patients with acute coronary syndromes (ACS). METHODS: Plasma cystatin C concentrations were determined within 24 hours of admission (baseline), at discharge, 1 month, and 6 months in the PLATO trial. The changes over time in relation to randomized treatment were analyzed by analysis of covariance. C-statistics and the relative Integrated Discrimination Improvement of the cystatin C concentrations regarding the primary outcome (cardiovascular death or myocardial infarction) was evaluated by multivariable analysis including background characteristics and biomarkers: N-terminal-pro-B-type natriuretic peptide and Troponin I. RESULTS: Mean cystatin C concentrations in 2133 ticagrelor- and 2162 clopidogrel-treated patients were at baseline (0.86 mg/L and 0.86 mg/L), discharge (1.01 mg/L and 0.98 mg/L) (P < .0005), 1 month (1.00 mg/L and 0.98 mg/L) (P = .12), and 6 months (1.00 mg/L and 0.99 mg/L) (P = .17), respectively. Age, heart failure, and type of ACS were major determinants of the cystatin C concentration. c Statistics and the relative Integrated Discrimination Improvement of the primary outcome for the baseline cystatin C concentration were 0.687 and 5.2%, compared to 0.684 and 4.5% at discharge (n = 4034) and 0.693 and 5.1% at one month (n = 3096), respectively. CONCLUSIONS: Mean cystatin C concentrations increased in ACS patients, most importantly determined by age. The initial greater increase in ticagrelor-treated patients was not sustained over time. Risk prediction did not improve with serial measurements of renal markers.

Duke Scholars

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

November 2012

Volume

164

Issue

5

Start / End Page

728 / 734

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Ticlopidine
  • Ticagrelor
  • Risk Factors
  • Purinergic P2Y Receptor Antagonists
  • Platelet Aggregation Inhibitors
  • Middle Aged
  • Male
  • Kidney Function Tests
  • Kidney
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Akerblom, A., Wallentin, L., Siegbahn, A., Becker, R. C., Budaj, A., Horrow, J., … James, S. K. (2012). Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study. Am Heart J, 164(5), 728–734. https://doi.org/10.1016/j.ahj.2012.08.017
Akerblom, Axel, Lars Wallentin, Agneta Siegbahn, Richard C. Becker, Andrzej Budaj, Jay Horrow, Steen Husted, et al. “Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study.Am Heart J 164, no. 5 (November 2012): 728–34. https://doi.org/10.1016/j.ahj.2012.08.017.
Akerblom A, Wallentin L, Siegbahn A, Becker RC, Budaj A, Horrow J, Husted S, Katus H, Claeys MJ, Storey RF, Asenblad N, James SK. Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study. Am Heart J. 2012 Nov;164(5):728–734.
Journal cover image

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

November 2012

Volume

164

Issue

5

Start / End Page

728 / 734

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Ticlopidine
  • Ticagrelor
  • Risk Factors
  • Purinergic P2Y Receptor Antagonists
  • Platelet Aggregation Inhibitors
  • Middle Aged
  • Male
  • Kidney Function Tests
  • Kidney